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Abstract
Background: Left ventricular hypertrophy (LVH) is a strong predictor of cardiovascular disease and is common
among patients with type 2 diabetes. However, no systematic screening for LVH is currently recommended for
patients with type 2 diabetes. The purpose of this study was to determine whether NT-proBNP was superior to
12-lead electrocardiography (ECG) for detection of LVH in patients with type 2 diabetes.
Methods: Prospective cross-sectional study comparing diagnostic accuracy of ECG and NT-proBNP for the
detection of LVH among patients with type 2 diabetes. Inclusion criteria included having been diagnosed for
> 5 years and/or on treatment for type 2 diabetes; patients with Stage 3/4 chronic kidney disease and known
cardiovascular disease were excluded. ECG LVH was defined as either the Sokolow-Lyon or Cornell voltage criteria.
NT-proBNP level was measured using the Roche Diagnostics Elecsys assay. Left ventricular mass was assessed from
echocardiography. Receiver operating characteristic curve analysis was carried out and area under the curve (AUC)
was calculated.
Results: 294 patients with type 2 diabetes were recruited, mean age 58 (SD 11) years, BP 134/81 ± 18/11 mmHg,
HbA1c 7.3 ± 1.5%. LVH was present in 164 patients (56%). In a logistic regression model age, gender, BMI and a
history of hypertension were important determinants of LVH (p < 0.05). Only 5 patients with LVH were detected by
either ECG voltage criteria. The AUC for NT-proBNP in detecting LVH was 0.68.
Conclusions: LVH was highly prevalent in asymptomatic patients with type 2 diabetes. ECG was an inadequate
test to identify LVH and while NT-proBNP was superior to ECG it remained unsuitable for detecting LVH. Thus,
there remains a need for a screening tool to detect LVH in primary care patients with type 2 diabetes to enhance
risk stratification and management.
Background
The complications of type 2 diabetes are common and
largely account for the excess morbidity and mortality
associated with this disease. As such routine screening
of asymptomatic patients with type 2 diabetes for retino-
pathy, nephropathy and neuropathy is recommended [1].
Diabetes is a major risk factor for coronary heart disease
and cardiovascular disease is the most important cause
of morbidity and mortality in patients with type 2
diabetes, accounting for approximately two-thirds of
total mortality [2]. In addition, type 2 diabetes mellitus
is associated with a cardiomyopathy characterised by left
ventricular hypertrophy (LVH) and diastolic dysfunction
[3]. However, current guidelines do not recommend
routine screening for structural heart disease in these
patients [1].
Diabetes is associated with LVH, left ventricular (LV)
diastolic dysfunction [4,5], LV systolic dysfunction and
cardiac autonomic neuropathy [3]. A large proportion of
patients with type 2 diabetes and no known cardiovascu-
lar disease have LVH [6]. LVH is an important risk fac-
tor for cardiovascular disease in the general population
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[7]. Regression of LVH by pharmacological intervention
is associated with an improvement in prognosis [8,9].
Therefore detection of LVH is attractive given the high
prevalence and hence high pre-test probability of LVH
in patients with type 2 diabetes.
In clinical practice the most reliable tool for quantifying
left ventricular mass and diagnosing LVH is transthoracic
echocardiography. Conversely the electrocardiogram
(ECG), though inexpensive and widely available, is of lim-
ited use in detecting LVH in patients with type 2 diabetes
due to its low sensitivity [10]. As both ECG and echocar-
diographic tools are currently unsuitable for wide popula-
tion screening, there is a need for an accessible,
acceptable, and economical test for detecting LVH in such
patients. Identification of patients with LVH would facili-
tate the commencement of therapies that reduce LV mass
and hence improve outcome. A biomarker, such as N-
terminal pro brain natriuretic peptide (NT-proBNP), may
be the solution. This simple and relatively inexpensive test
can be measured from a non-fasting venous blood sample.
NT-proBNP is released from the heart under conditions
of increased wall stress [11] and is used primarily in the
diagnosis of heart failure in patients with dyspnoea.
Amongst patients with type 2 diabetes, higher BNP levels
were observed in those with LVH [12].
Recent data suggests that NT-proBNP may be of value
in identification of LVH among patients with hyperten-
sion presenting to emergency departments [13]. How-
ever, to date there have been no studies comparing
diagnostic accuracy between NT-proBNP and ECG for
detection of LVH in patients with type 2 diabetes. This
study aimed to determine the value of NT-proBNP in
the detection of LVH among patients with type 2 dia-
betes and no known cardiovascular disease in primary
care.
Methods
In this investigator-initiated study, all researchers were
independent of the funding bodies and had complete
access to all data. Ethics approval was obtained from the
Northern Y Regional Ethics Committee (New Zealand).
During a 14-month period (March 2006 - May 2007),
294 patients with type 2 diabetes diagnosed by their gen-
eral practitioner, of at least 5 years duration and/or on
treatment for type 2 diabetes, were prospectively
recruited from primary care. Patients with known cardiac
disease (including coronary heart disease, heart failure,
LVH (identified on previous ECG or echo done for clini-
cal purposes), moderate and severe valvular heart disease,
atrial fibrillation), cerebrovascular disease (prior stroke or
transient ischaemic attack), peripheral arterial disease,
Stage 3 chronic kidney disease (eGFR < 60 mL/min) or
inability to provide informed consent were excluded. A
general practitioner (GP) network previously developed
in the Natriuretic Peptides in the Community study [14]
was used to facilitate recruitment of primary care
patients. Patients meeting study inclusion and exclusion
criteria were identified and referred to the study centre
by 51 participating GPs within the Auckland region.
Study personnel contacted referred patients, provided
further details regarding the study and invited them to a
study visit.
All patients were seen and evaluated in the Cardiovas-
cular Research Clinic at The University of Auckland.
During the study visit patient eligibility was confirmed
and informed consent was obtained. Basic demographics
and medical history including information regarding
known microvascular complications of type 2 diabetes
were recorded. The mean of three seated blood pressure
(BP) measurements, separated by a minimum interval of
five minutes, was obtained. Height, body mass, waist cir-
cumference, hip circumference, and body composition
were measured. Blood was collected using standard
venepuncture technique and samples were sent to a ter-
tiary referral medical laboratory for measurement of
creatinine, glucose, HbA1c, lipids, and NT-proBNP. A
single urinary albumin:creatinine ratio measured within
12 months of the study visit was obtained from commu-
nity laboratories. If this was unavailable, participants
were directed to have this done soon after the study
visit.
All patients had a resting transthoracic echocardio-
gram (Philips HDI 5000/iE33, Bothell, Seattle, Washing-
ton) which was the reference standard for the detection
of LVH in this study performed by a research-trained
sonographer. LV mass was assessed from M-mode
images in accordance with The American Society of
Echocardiography (ASE) guidelines [15]. When M-mode
images were unsuitable for measurement, 2-dimensional
images were used. The LV mass gender-specific cut-offs
for LVH used were: >45 g/m2.7 in women and >49 g/
m2.7 in men[15]. All echocardiographic measurements
were made by a cardiologist with subspecialty training
in echocardiography. For LV mass the coefficient of
variability for intra-observed repeated measures is less
than 8% [16]. The echocardiographer and cardiologist
measuring the images were blinded to ECG and NT-
proBNP results.
All patients had a standard unfiltered 12-lead ECG
(Philips Hewlett-Packard PageWriter 200 Cardiograph,
Andover, Massachusetts). Each ECG was measured by a
single analyst using a 150 mm digital vernier calliper
under a five-fold magnification. ECG criteria used for
the detection of LVH included the Sokolow-Lyon (SV1 +
RV5/6)[17] and Cornell (women RaVL + SV3 + 0.8 mV;
men RaVL + SV3)[18] voltage criteria. Standard cut-
offs for the electrocardiographic diagnosis of LVH
were used: Sokolow-Lyon voltage >3.5 mV[17] and
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Cornell voltage >2.8 mV[18]. Patients meeting either
criterion were considered to have LVH by ECG. The
ECG analyst was blinded to echocardiographic and
NT-proBNP results. Thirty participants were randomly
selected for estimation of test reproducibility. This
analysis demonstrated an intra-observer and inter-
observer variability of ≤0.01 mV for measurement of
ECG voltages.
NT-proBNP levels were measured using the Roche
Diagnostics Elecsys assay (pmol/L). The performance
characteristics claimed by the manufacturer are an ana-
lytical sensitivity of 0.6 pmol/L and functional sensitivity
of <5.9 pmol/L.
Statistical methods
In the Casale Monferrato Study [19] the prevalence of
ECG LVH was 17%. Assuming 90% power approxi-
mately 200 patients with diabetes and no LVH and 50
patients with diabetes with LVH would resolve an area
under a Receiver Operating Characteristic (ROC) curve
(AUC) of 0.8 and 0.9 between ECG LVH and NT-
proBNP. To allow for information not being available
from all patients the sample size was 300 subjects.
Normally distributed variables are presented as mean
(standard deviation) and significantly skewed variables
as median (interquartile range). Receiver operating char-
acteristic (ROC) curve analyses were performed to eval-
uate the diagnostic performance of NT-proBNP in the
detection of LVH, with sub-analyses on the basis of age,
gender, BMI and albuminuria. The area under the curve
(AUC) was used to assess the discriminative ability of
NT-proBNP. Sensitivity, specificity, predictive values and
the positive likelihood ratio are calculated at the thresh-
old determined by the maximal Youden index.
Multivariable logistic regression was used to investi-
gate the relationship between patient factors and LVH.
Variables were selected for inclusion in the model on
the basis of biological plausibility. The natural logarithm
of NT-proBNP was used to satisfy model assumptions.
Analyses were performed using SAS 9.1 (SAS Institute
Inc, Cary, NC, USA) statistical software.
Results
Of the 365 potential participants referred by 51 general
practitioners, 60 were ineligible, uncontactable or did not
attend their study visit (Figure 1). A further 11 partici-
pants were excluded due to permanent atrial fibrillation,
Stage 3 chronic kidney disease, known LVH, previous
stroke or failing to satisfy inclusion criteria. The remain-
ing 294 participants were included in the study. The
mean age of participants was 58 ± 11 years, 49% were
women, 42% were Caucasian, 33% were Polynesian
(Mäori and Pacific Islander) and 25% were Asian. Mean
body mass index (BMI) was 31.9 ± 7.0 kg/m2 and mean
BP 134/81 ± 18/11 mmHg. Median time since diagnosis
of type 2 diabetes was 6 years (range 1 month - 50 years).
Mean HbA1c 7.3 ± SD 1.5% and median urinary albumin:
creatinine ratio (UACR) was 1.2 (IQR 0.4, 4.0) mg/mmol.
One hundred and eighty nine (66%) participants had a
normal UACR (<2.5 mg/mmol), 72 (25%) had microalbu-
minuria (UACR 2.5 - 20 mg/mmol) and 27 (9%) had
macroalbuminuria (UACR >20 mg/mmol). A history of
known retinopathy was noted in 14%, nephropathy
in 11% and neuropathy in 8%. Many participants had a
history of other cardiovascular risk factors such as hyper-
tension (60%) and dyslipidaemia (70%). Half of all partici-
pants were prescribed aspirin, 61% a statin and 47% an
angiotensin converting enzyme (ACE) inhibitor. Nearly
all patients were on pharmacological therapy for type
2 diabetes (94%): 244 were on oral hypoglycaemic ther-
apy alone, 6 on subcutaneous insulin therapy alone and
25 on both. Of the 269 participants on oral hypoglycae-
mic therapy, 243 (90%) were on metformin, 130 (48%) on
a sulphonylurea, 8 (3%) on a thiazolidinedione and 1 on
acarbose. (See Table 1)
The mean LV mass index was 51.5 ± 14.6 g/m2.7. LVH
was diagnosed by echocardiography in 164 of the 294
participants (56%). Using the ASE partition values of LV
mass index [15], 52 participants (18%) had mild LVH
(women 45-51 g/m2.7, men 49-55 g/m2.7), 49 (17%)
moderate LVH (women 52-58 g/m2.7, men 56-63 g/m2.7)
and 63 (21%) severe LVH (women ≥59 g/m2.7, men
≥64 g/m2.7). Of the 119 participants with no previous
history of hypertension, 44 (37%) had LVH. Participants
on either an ACE inhibitor or angiotensin receptor
blocker were more likely to have LVH (62% vs. 49%).
The European Society of Hypertension (ESH) and
European Society of Cardiology (ESC) 2007 Guidelines
for the Management of Arterial Hypertension use LV
mass index thresholds of 110 g/m2 for women and
125 g/m2 for men to diagnose LVH [20]. By this more
conservative definition, 79 (27%) had LVH. (See Table 1)
Important incidental findings on echocardiography
included a resting regional wall motion abnormality in 17
(6%) and LV systolic dysfunction in 12 (4%). LV diastolic
dysfunction, as assessed by mitral filling pattern, demon-
strated abnormal relaxation in 173 (59%) and pseudonor-
mal filling in 87 (30%) of patients. (See Table 1)
Detection of left ventricular hypertrophy
Only 4 of the 164 participants (2%) with known echocar-
diographic LVH were correctly detected by either the
Sokolow-Lyon or Cornell voltage criteria. The sensitivity of
ECG for detecting echocardiographic LVH was 2% (95%
CI 1 to 6%) with a specificity of 99% (95% CI 96 to 100%).
The median NT-proBNP level was 6.0 pmol/L (range
of <0.6-175.0). The area under the curve (AUC) for
NT-proBNP in discriminating patients with LVH from
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those with no LVH was 0.68 (95% CI 0.62 to 0.74)
(Figure 2). The maximum Youden index was established
at an NT-proBNP level of 4.4 pmol/L (37.3 pg/mL). At
this cut off the sensitivity was 68% (95% CI 60 to 75%)
and the specificity was 58% (95% CI 50 to 68%). There
was no improvement in the performance of NT-proBNP
in distinguishing between patients with moderate-severe
LVH and those with no LVH-mild LVH (AUC 0.64).
Similarly, using the ESH/ESC definition of LVH, there
was no difference in the utility of NT-proBNP in identi-
fying patients with LVH (AUC 0.64). When participants
were categorised into three groups [normal UACR (<2.5
mg/mmol), microalbuminuria (UACR 2.5 - 20.0 mg/
mmol) and macroalbuminuria (UACR >20 mg/mmol)]
the median NT-proBNP level was similar: 6.0 (IQR 3.0 -
12.0) pmol/L, 6.0 (IQR 3.0-16.5) pmol/L and 8.0 (IQR
3.0 - 21.0) pmol/L respectively.
There was some variability in the diagnostic accuracy of
NT-proBNP between subgroups of participants (Figure 2).
For example, the AUC was higher in women (0.72 vs. 0.61)
and in those with a BMI below the median of 30.8 kg/m2
(0.78 vs. 0.56). There was no difference in AUC for patients
with UACR ≥2.5 mg/mmol (0.68) and <2.5 mg/mmol
(0.69).
In a multivariable model including age, gender, history
of hypertension, time since diagnosis of type 2 diabetes,
BMI, HbA1c, the presence of albuminuria, and loge (NT-
proBNP), the significant determinants of LVH were: BMI
(c2 24.7; <0.001), age (c2 8.3; p = 0.004), history of hyper-
tension (c2 4.9; p = 0.028), and gender (c2 4.1; p = 0.043).
Discussion
This study, involving a group of patients with type 2
diabetes with no known cardiac, cerebrovascular or per-
ipheral vascular disease, has demonstrated that LVH
(defined according to the ASE guidelines [15]) was com-
mon, occurring among 56% of the patients. The detec-
tion of LVH by standard ECG criteria was poor and
while NT-proBNP was superior to ECG in discriminat-
ing LVH, it remains unsuitable for use as a screening
tool due to inadequate optimum sensitivity and
specificity.
Clinical importance of left ventricular hypertrophy
The prevalence of LVH in patients with type 2 diabetes
has varied considerably based on the mode of detection
and baseline characteristics of the cohort studied. The
high proportion (56%) of participants with LVH in this
Figure 1 Participant flow. Abbreviations: AF atrial fibrillation, eGFR estimated glomerular filtration rate, LVH left ventricular hypertrophy
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study is comparable with previously reported data. For
example, echocardiographic LVH was found in 22% [12]
and 51% [21] of Australian diabetes clinic attendees. A
higher prevalence of echocardiographic LVH (71%) was
noted in diabetes clinic attendees in Dundee, Scotland
[22], although a lower proportion (9.4%) among patients
with diabetes without known macrovascular complica-
tions in a recent study from Sweden [4]. In our study
37% of participants with no history of hypertension had
LVH; suggesting that type 2 diabetes per se is associated
with LVH. More importantly the clinically prevalent
combination of type 2 diabetes and hypertension was
strongly linked to the development of LVH, occurring in
69% of such patients.
The relationship between LVH and poor prognosis [7]
would suggest that this common finding in patients with
type 2 diabetes is clinically significant. For example in
the Reduction of End Points in Non-insulin Dependent
Diabetes Mellitus with the Angiotensin II Antagonist
Losartan (RENAAL trial), LVH was associated with an
increased risk of death, end-stage renal disease and dou-
bling of serum creatinine (hazard ratio 1.41; p < 0.001)
in patients with type 2 diabetes, clinical nephropathy
and no known cardiovascular disease [23].
LVH is emerging as an important independent thera-
peutic target. Treatment with losartan was associated
with a reduction in ECG LVH in the RENAAL trial
[23]. A change in LVH voltage criteria was an indepen-
dent predictor of cardiovascular events in hypertensive
patients with diabetes in the Appropriate Blood Pressure
Control in Diabetes (ABCD) trial [24]. These data pro-
vide some hope that, in asymptomatic patients with type
2 diabetes, the aggressive treatment of LVH per se or
risk factors for LVH, such as hypertension, may yield
significant long term prognostic benefits. A substudy of
the Losartan Intervention For Endpoint Reduction in
Hypertension (LIFE) study focussing on patients with
diabetes suggested that patients with diabetes experi-
enced less regression of LVH in response to losartan
and any regression was not predictive of future cardio-
vascular events [25]. The increased formation of
advanced glycation end products and their cross-linking
with myocardial collagen associated with diabetes was
proposed as a mechanism to account for this difference.
This highlights the need to develop other therapies spe-
cifically targeting LVH, independent of BP lowering,
such as advanced glycation end product-protein break-
ers [26].
Detection of left ventricular hypertrophy
ECG
The 12-lead ECG, the most commonly used tool for
diagnosis of LVH in the community, performed poorly
in detecting LVH compared to echocardiography. The
most widely used ECG criteria are the Sokolow-Lyon
voltage criteria. Using these criteria, the prevalence of
LVH in this cohort would only be 1%. The combination
of both the Sokolow-Lyon and the Cornell voltage cri-
teria only raised the prevalence to 1.7%. Similarly in the
Scottish study of diabetes clinic patients, in whom the
prevalence of echocardiographic LVH was 71%, the pre-
valence of ECG LVH using the LIFE criteria was only
9.2% [22]. The poor performance of ECG in detecting
LVH, using voltage-based criteria, may result from the
attenuation of electrocardiographic voltages at the skin
surface by increased fat mass in obese individuals [27].
In our study participants with a higher BMI were found
to have a higher prevalence of echocardiographic LVH
(73% vs. 39%), yet lower mean Sokolow-Lyon voltages
(1.7 mV vs. 1.9 mV) and the same mean Cornell vol-
tages (1.2 mV).
Table 1 Patient characteristics
Clinical
Female, n 145 (49%)
Age, years (SD) 58 (11)
Median duration of diabetes, months (IQR) 72 (36, 120)
History of hypertension, n 175 (60%)
History of dyslipidaemia, n 206 (70%)
Body mass index, kg/m2 (SD) 31.9 (7.0)
Systolic blood pressure, mmHg (SD) 134 (18)
Diastolic blood pressure, mmHg (SD) 81 (11)
HbA1c, % (SD) 7.3 (1.5)
Median UACR, mg/mmol (IQR) 1.2 (0.4, 4.0)
Normal UACR (<2.5 mg/mmol), n 189 (66%)
Microalbuminuria (UACR 2.5 - 20 mg/mmol), n 72 (25%)
Macroalbuminuria (UACR ≥20 mg/mmol), n 27 (9%)
Current therapy
Oral hypoglycaemic therapy, n 269 (91%)
Subcutaneous insulin therapy, n 31 (11%)
Any antihypertensive therapy, n 190 (65%)
Statin therapy, n 178 (61%)
Echocardiographic characteristics
Left ventricular mass, g (SD) 207 (63)
Left ventricular mass index, g/m2.7 (SD) 51.5 (14.6)
Left ventricular hypertrophy, n 164 (56%)
Mild, n 52 (18%)
Moderate, n 49 (17%)
Severe, n 63 (21%)
Regional wall motion abnormality, n 17 (6%)
Left ventricular systolic dysfunction, n 12 (4%)
Left ventricular diastolic dysfunction, n 260 (89%)
Abnormal relaxation, n 173 (59%)
Pseudonormal filling, n 87 (30%)
Values represent mean unless stated. Abbreviations: IQR interquartile range,
SD standard deviation, UACR urinary albumin:creatinine ratio.
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NT-proBNP
Though NT-proBNP was far superior to ECG in detect-
ing LVH it was inadequate for general use as a screen-
ing tool for LVH in community patients with type 2
diabetes and no overt cardiovascular disease. One possi-
ble explanation for the poor performance of NT-
proBNP in detecting LVH in this study relates to the
low levels of NT-proBNP levels (median 6.0 pmol/L) in
comparison to diagnostic cut-offs for heart failure [14].
This may relate to the both the obese nature of this
cohort (mean BMI 31.9 kg/m2) as well as the prevalence
of metabolic risk factors. Metabolic risk factors have
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Figure 2 Receiver operating characteristic curves for NT-proBNP in discriminating left ventricular hypertrophy for whole group (A)
and according to: gender (B); body mass index (BMI, C); presence of albuminuria (urinary albumin:creatinine ratio ≥2.5 mg/mmol, D)
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previously been independently associated with lower
natriuretic peptide levels [28]. Thus the release of NT-
proBNP promoted by LVH in our patients may well
have been dampened by the counterinfluence of obesity
and metabolic risk factors. Recently data has suggested
that a combined approach using ECG and NT-proBNP
can improve identification of LVH among patients with
hypertension presenting to emergency departments [13].
However, this study was from a small number of
patients (49) among whom 43% had LVH from the ECG
and while promising these results would need to be con-
firmed in a larger study and this approach has not been
evaluated among patients with diabetes.
The functional sensitivity, the lowest concentration
that can be reliably measured with a between-run coeffi-
cient variation of 20%, of the NT-proBNP assay (<5.9
pmol/L) employed in this study may have significantly
decreased the performance of NT-proBNP in detecting
LVH. Approximately half of this cohort had a NT-
proBNP measurement below the functional sensitivity.
The imprecise nature of the assay at these low concen-
trations may conceal the true relationship between LVH
and NT-proBNP level in this cohort. The optimal statis-
tical NT-proBNP cut-off for the detection of LVH (4.4
pmol/L using the maximum Youden index) is not clini-
cally useful as it well below the functional sensitivity of
the available assay.
Future approaches
Given the poor performance of current ECG LVH cri-
teria and NT-proBNP in detecting echocardiographic
LVH there is a need for the development of alternative
methods for detecting this prevalent complication which
is associated with an adverse prognosis. The main lim-
itation of current voltage-based ECG LVH criteria
appears to be the attenuation of electrocardiographic
voltages at the skin surface by subcutaneous fat. Index-
ing voltages to measures of body composition, such as
body fat percentage, may help adjust for the attenuation
of voltages by increased body fat and increase the utility
of current voltage criteria in obese individuals. At pre-
sent the Framingham-adjusted Cornell voltage criteria is
the only available ECG LVH criteria adjusting for a
measure of body size by incorporating BMI [29]. Other
voltage-independent ECG LVH, such as QRS duration
and QT interval, require further investigation this
population.
Another possible tool for the detection of LVH in the
community is hand-carried echocardiography (HCE). This
is a cheaper, user-friendly and more accessible alternative
to standard transthoracic echocardiography. A limited
echocardiographic study using HCE may be a valuable
screening tool for not just LVH but also resting regional
wall motion abnormalities, significant LV systolic and
diastolic dysfunction in a group of asymptomatic indivi-
duals at high risk of cardiovascular disease. This would
require further prospective evaluation.
Limitations
Systematic assessment for silent myocardial ischaemia
was not assessed in this study and hence its confound-
ing influence is uncertain. Chronic stable coronary heart
disease is known to be associated with higher natriuretic
peptide levels[30]. Though patients with known coron-
ary heart disease were excluded from our study we did
not assess or exclude patients with silent myocardial
ischaemia. While silent myocardial ischaemia may have
been a confounding factor we believe that it has not sig-
nificantly altered the overall results or conclusions of
this study given the low NT-proBNP levels observed.
The quality of ECG recordings is important for accu-
rate detection of LVH. In this study all ECG recordings
were performed by staff that were trained and super-
vised by a registered technologist and using a state-of-
the-art machine. Furthermore, all measurements were
performed by a single observer according to protocol
and quality reviewed by a cardiologist. Lastly, it is possi-
ble that the failure to detect LVH was related to the
over-estimation of LVH by echocardiography. This is
unlikely since the echoes were performed according to a
strict protocol and reviewed and measured by a trained
echocardiologist, and the prevalence of LVH is similar
to other published cohorts.
Conclusion
In conclusion, LVH was highly prevalent in asympto-
matic patients with type 2 diabetes. ECG was an inade-
quate test to identify LVH in these patients. NT-
proBNP though superior to ECG remains unsuitable as
a screening tool to detect LVH in patients with type 2
diabetes. There remains a need for a screening tool to
detect LVH in patients with type 2 diabetes in primary
care to enhance risk stratification and management.
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